Available Technologies
# of Displayed Technologies: 2 / 2
Applied Category Filter (Click To Remove): Other
Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
- College: College of Medicine (COM)
- Inventors: Kerur, Nagaraj
- Licensing Officer: Schultz, Teri
Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells.
The Need
Current therapies…
- College: College of Medicine (COM)
- Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
- Licensing Officer: Schultz, Teri
